Prosecution Insights
Last updated: April 19, 2026

Accutar Biotechnology Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
1
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18476063 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS SEITZ, ANTHONY JOSEPH 1629 Non-Final OA Sep 27, 2023
18263656 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS WILLIS, DOUGLAS M 1624 Non-Final OA Jul 31, 2023
17587212 MOLECULAR MODELING WITH MACHINE-LEARNED UNIVERSAL POTENTIAL FUNCTIONS HOCKER, JOHN PAUL 2189 Final Rejection Jan 28, 2022

Managing Accutar Biotechnology Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month